doctors

Not Enough Doctors?

Industry Insights from Paul Meade, M.Sc, MPH Recently, I read a Wall Street Journal op-ed piece titled “Why the Doctor Can’t See You” by John Goodman, President of the National Center for Policy Analysis.  The central point of Goodman’s piece suggests that under the Affordable Care Act the “demand for healthcare will increase dramatically,” and …

Not Enough Doctors? Read More »

Thought Leader Select Announces New KOL Identification and Profiling Projects in Oncology, Neurology

Thought Leader Select is pleased to announce a series of key opinion leader (KOL) identification and profiling projects to support multiple therapeutic areas for a top five global biopharmaceutical company. In these research assessments, Thought Leader Select will identify and profile leading medical experts in neurology and oncology to support drug development initiatives in various …

Thought Leader Select Announces New KOL Identification and Profiling Projects in Oncology, Neurology Read More »

Thought Leader Select Announces New Assessments of Key Opinion Leaders, Centers of Excellence in Women’s Health, Oncology

Company News Thought Leader Select is pleased to announce a pair of projects in support of a top 10 global biopharmaceutical company as it seeks to develop a portfolio of medicines in women’s health. For the assessments, Thought Leader Select will study key opinion leaders and medical centers of excellence in the treatment of cancers …

Thought Leader Select Announces New Assessments of Key Opinion Leaders, Centers of Excellence in Women’s Health, Oncology Read More »

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Four

Pharmaceutical & Biotechnology Companies Provide Early Knowledge-building Opportunities for KOLs and Clinical Investigators Understanding the value that key opinion leaders provide pharmaceutical and biotechnology companies is clear, but how do companies benefit thought leaders and clinical investigators? By definition, KOLs are physicians, scientists and academics who devote time to studying and advancing their craft. Often, …

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Four Read More »